ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2017
February 05 2018 - 5:10PM
ImmuCell Corporation (Nasdaq:ICCC) (“ImmuCell” or
the “Company”), a growing animal health company that develops,
manufactures and markets scientifically-proven and practical
products that improve the health and productivity of dairy and beef
cattle, will report financial results for the fourth quarter of
2017 after the market closes on Thursday, February 8, 2018.
The Company has scheduled a conference call that same day,
Thursday, February 8, 2018, at 4:30 PM ET to review the results.
Interested parties can access the conference call by dialing
(844) 855-9502 (toll free) or (412) 317-5499 (international). A
teleconference replay of the call will be available for six days at
(877) 344-7529 (toll free) or (412) 317-0088 (international),
utilizing confirmation # 10116765.
About ImmuCell: ImmuCell Corporation's
(Nasdaq:ICCC) purpose is to create scientifically-proven and
practical products that improve the health and productivity of
dairy and beef cattle. ImmuCell has developed products that
provide significant, immediate immunity to newborn dairy and beef
livestock. The Company is developing a novel treatment for
mastitis, the most significant cause of economic loss to the dairy
industry. Press releases and other information about the
Company are available at: http://www.immucell.com.
Safe Harbor Statement:
This Press Release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to:
projections of future financial performance; the scope and timing
of ongoing and future product development work and
commercialization of our products; future costs of product
development efforts; the estimated prevalence rate of subclinical
mastitis; the expected efficacy of new products; future market
share of and revenue generated by current products and products
still in development; future sources of financial support for our
product development, manufacturing and marketing efforts; the
future adequacy of our own manufacturing facilities or those of
third parties with which we have contractual relationships to meet
demand for our products on a timely basis; the future adequacy of
our working capital and the availability and cost of third party
financing; timing and future costs of a facility to produce the
Drug Substance (our active pharmaceutical ingredient, Nisin); the
timing and outcome of pending or anticipated applications for
regulatory approvals; future regulatory requirements relating to
our products; future expense ratios and margins; future compliance
with bank debt covenants; costs associated with sustaining
compliance with cGMP regulations in our current operations and
attaining such compliance for the facility to produce the Drug
Substance; factors that may affect the dairy and beef industries
and future demand for our products; our effectiveness in competing
against competitors within both our existing and our anticipated
product markets; the cost-effectiveness of additional sales and
marketing expenditures and resources; the accuracy of our
understanding of our distributors’ ordering patterns; anticipated
changes in our manufacturing capabilities and efficiencies;
anticipated competitive and market conditions; and any other
statements that are not historical facts. Forward-looking
statements can be identified by the use of words such as “expects”,
“may”, “anticipates”, “aims”, “intends”, “would”, “could”,
“should”, “will”, “plans”, “believes”, “estimates”, “targets”,
“projects”, “forecasts” and similar words and expressions. In
addition, there can be no assurance that future developments
affecting us will be those that we anticipate. Such statements
involve risks and uncertainties, including, but not limited to,
those risks and uncertainties relating to difficulties or delays in
development, testing, regulatory approval, production and marketing
of our products, competition within our anticipated product
markets, customer acceptance of our new and existing products,
product performance, alignment between our manufacturing resources
and product demand, the uncertainties associated with product
development and Drug Substance manufacturing, actual as compared to
expected or estimated costs of expanding our manufacturing
facilities, our potential reliance upon third parties for financial
support, products and services, changes in laws and regulations,
decision making by regulatory authorities, possible dilutive
impacts on existing stockholders from any equity financing
transactions in which we may engage, currency values and
fluctuations and other risks detailed from time to time in filings
we make with the Securities and Exchange Commission, including our
Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and
our Current Reports on Form 8-K. Such statements are based on our
current expectations, but actual results may differ materially due
to various factors, including the risk factors discussed above.
Contact:
Michael F. Brigham, President and CEOImmuCell Corporation(207)
878-2770
Joe Diaz, Robert Blum and Joe DorameLytham Partners, LLC(602)
889-9700iccc@lythampartners.com
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2023 to Apr 2024